Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer
Lancet Oncol
.
2019 Jun;20(6):746-748.
doi: 10.1016/S1470-2045(19)30279-7.
Epub 2019 Apr 27.
Authors
Seth A Wander
1
,
Laura M Spring
1
,
Aditya Bardia
2
Affiliations
1
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
2
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: bardia.aditya@mgh.harvard.edu.
PMID:
31036469
DOI:
10.1016/S1470-2045(19)30279-7
No abstract available
Publication types
Comment
MeSH terms
Androstadienes
Breast Neoplasms*
Double-Blind Method
Histone Deacetylase Inhibitors
Histone Deacetylases*
Humans
Postmenopause
Substances
Androstadienes
Histone Deacetylase Inhibitors
Histone Deacetylases
exemestane